聚焦美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性。We rate SMMT Underperform with PT $7.70 (-56%) based on our DCF valuation.Key messages:1. We expect HARMONi6’s ASCO presentation to show non-statistically significant overall survival at interim analysis: OS trend HR >0.722 is likely in the absence of a pre-conference press release.
聚焦美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性。We rate SMMT Underperform with PT $7.70 (-56%) based on our DCF valuation.Key messages:1. We expect HARMONi6’s ASCO presentation to show non-statistically significant overall survival at interim analysis: OS trend HR >0.722 is likely in the absence of a pre-conference press release.
聚焦美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性。We rate SMMT Underperform with PT $7.70 (-56%) based on our DCF valuation.Key messages:1. We expect HARMONi6’s ASCO presentation to show non-statistically significant overall survival at interim analysis: OS trend HR >0.722 is likely in the absence of a pre-conference press release.
覆盖 2026 年,全文共 50 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
适合行业研究员、战略规划等读者参考。
重点分析了生物制药、会展、美国中型生物制药、Summit等议题。